<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992781</url>
  </required_header>
  <id_info>
    <org_study_id>A3921330</org_study_id>
    <nct_id>NCT03992781</nct_id>
  </id_info>
  <brief_title>Changes of Depression After First-year of Tofacitinib in RA Patients</brief_title>
  <official_title>NON-INTERVENTIONAL STUDY TO REVIEW THE CHANGES OF DEPRESSION AFTER FIRST-YEAR OF TOFACITINIB TREATMENT IN RHEUMATOID ARTHRITIS (XELJANZ (Registered))</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      12-month, single arm, prospective, non-interventional, multi-center study according to Czech&#xD;
      legal definitions (Law 378/2007 Sb.).The primary objective of this study is to describe and&#xD;
      evaluate the changes of depression level within 12 months from the start of tofacitinib&#xD;
      therapy in patients with RA and at least minimal level of depression. Primary goal is to find&#xD;
      out if treatment by tofacitinib reduces the depression by at least 10% during 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2020</start_date>
  <completion_date type="Anticipated">January 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient Self Assessment of Clinically Useful Depression Outcome Scale (CUDOS)</measure>
    <time_frame>Baseline, Visit 3 (12 months after start of Tofacitinib treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline value and relative change between visit 2 and baseline of CUDOS score</measure>
    <time_frame>Baseline, Visit 2 (6 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinically Useful Anxiety Outcome Scale (CUXOS) for evaluation of anxiety</measure>
    <time_frame>Baseline, Visit 2, Visit 3 (6 months and 12 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Jenkins Sleep Evaluation Questionnaire (JSEQ) for evaluation of insomnia</measure>
    <time_frame>Baseline, Visit 2, Visit 3 (6 months and 12 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Scale (VAS) score for evaluation of arthritis pain</measure>
    <time_frame>Baseline, Visit 2, Visit 3 (6 months and 12 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of concomitant medication (antidepressants, analgesics, anxiolytics and hypnotics) together with doses for each and the change in number of used medicaments and in their dosage</measure>
    <time_frame>Baseline, Visit 3 (12 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change of DAS28 4 (Erythrocyte sedimentation rate (ESR))</measure>
    <time_frame>Baseline, Visit 2, Visit 3 (6 months and 12 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change of DAS28 4 (C reactive protein (CRP))</measure>
    <time_frame>Baseline, Visit 2, Visit 3 (6 months and 12 months after start of Tofacitinib treatment)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Newly prescribed tofacitinib</arm_group_label>
    <description>patients who were newly prescribed tofacitinib at baseline and who scored at least 11 points on CUDOS scale</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis who are initiated on tofacitinib as part of a usual care&#xD;
        setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥18 years.&#xD;
&#xD;
          -  Moderate to severe activity of rheumatoid arthritis (DAS28 ≥3.2).&#xD;
&#xD;
          -  Patient for whom the physician decision has been made to initiate a treatment with&#xD;
             Tofacitinib.&#xD;
&#xD;
          -  Patient with at least minimal level of depression (CUDOS questionnaire ≥11 points).&#xD;
&#xD;
          -  Capable of understanding and signing a written informed consent form.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient (or a legally acceptable representative) has been informed of all&#xD;
             pertinent aspects of the study is a requirement for inclusion into this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling/unable to fill in printed patient questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Prague</city>
        <state>Czech Republic</state>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheuma s.r.o.</name>
      <address>
        <city>Breclav</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revmatologie s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>63800</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mangala Hospital &amp; Mangala Kidney Foundation</name>
      <address>
        <city>Karlovy Vary</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artroscan, s.r.o.</name>
      <address>
        <city>Ostrava - Trebovice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>12800</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Sumperk</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revmatologicke centrum s.r.o.</name>
      <address>
        <city>Velke Bilovice</city>
        <zip>69102</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A3921330</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

